stonks4u
Sign up free
PCVX logo

PCVX Vaxcyte, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$58.07
-0.79 (-1.34%)

Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive p…

Market Cap: $8.39Bvaxcyte.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

95
95
Aug 16Aug 16

Quote

Day Range
$57.47 – $58.59
52-Week Range
$29.87 – $65.00
Volume
$656.6K
Market Cap
$8.39B
50-Day Avg
$54.67
200-Day Avg
$52.79
Prev Close
$58.86
Open
$58.59

Valuation & Ratios

P/E Ratio
-8.20
EPS
$-5.63
P/B Ratio
2.34
P/S Ratio
0.00
Debt/Equity
0.09
Current Ratio
7.91
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-28.5%
Return on Assets
-25.2%
FCF Yield
-10.7%
EV/EBITDA
-8.54

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-766.63M$-5.63
2024$0.00$-463.93M$-3.80
2023$0.00$-402.27M$-4.14
2022$0.00$-223.49M$-3.44
2021$0.00$-100.08M$-1.93

Social Signal Score

45
5d
46
1 mentions
—
30d
45
1 mentions
—
60d
45
1 mentions
—
90d
45
1 mentions
—
news: 1

Earnings

Tue, Nov 3(in 3 months)

Consensus estimate $-2.12 per share

2of 7 quarters beat consensus

Typical surprise -8.9% (median, so one quarter with a near-zero estimate can't distort it)

  • Wed, Aug 5$-1.97 vs $-2.06beat
  • Wed, May 6$-2.30 vs $-1.78miss
  • Tue, Feb 24$-1.80 vs $-1.53miss
  • Tue, Nov 4$-1.56 vs $-1.27miss
  • Wed, Aug 6$-1.22 vs $-1.12miss
  • Wed, May 7$-1.04 vs $-1.02miss

Estimates and results for PCVX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Insider trading

Open-market buys and sells by PCVX officers and directors.

Bought
—

0 trades

Sold
$7.5m

38 trades

  • Dhaliwal Harpreet S.sold
    Chief Technical Ops Officer·17,000 @ $55.00·$935k·Aug 5, 2026·filing
  • Wassil Jimsold
    CHIEF OPERATING OFFICER·861 @ $53.50·$46k·Aug 3, 2026·filing
  • Wassil Jimsold
    CHIEF OPERATING OFFICER·1,389 @ $54.09·$75k·Aug 3, 2026·filing
  • Guggenhime Andrewsold
    PRESIDENT AND CFO·6,956 @ $53.76·$374k·Aug 3, 2026·filing
  • Guggenhime Andrewsold
    PRESIDENT AND CFO·3,044 @ $54.18·$165k·Aug 3, 2026·filing
  • Pickering Grantsold
    director, officer: CHIEF EXECUTIVE OFFICER·11,783 @ $55.52·$654k·Jul 27, 2026·filing
  • Pickering Grantsold
    director, officer: CHIEF EXECUTIVE OFFICER·4,415 @ $55.93·$247k·Jul 27, 2026·filing
  • Pickering Grantsold
    director, officer: CHIEF EXECUTIVE OFFICER·622 @ $55.54·$35k·Jul 27, 2026·filing

62 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.

Valuation

PCVXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • News247wallst.com·6h ago·Neutral

    If You Followed Seth Klarman Into Vaxcyte in May, He Was Already Long Gone Seth Klarman's Baupost Group eliminated its entire stake in Vaxcyte (NASDAQ:PCVX | PCVX Price Prediction) during the June quarter, according to the 13F filed August 13, 2026.

    View source ↗